{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:39:35Z","timestamp":1779212375582,"version":"3.51.4"},"reference-count":142,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100003093","name":"Fundamental Research Grant Scheme (FRGS), Ministry of Higher Education","doi-asserted-by":"publisher","award":["FRGS\/1\/2021\/SKK0\/UCSI\/02\/5"],"award-info":[{"award-number":["FRGS\/1\/2021\/SKK0\/UCSI\/02\/5"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Natural cyclodextrins (CDs) are macrocyclic starch molecules discovered a decade ago,\nin which \u03b1-, \u03b2-, and \u03b3-CD were commonly used. They originally acted as pharmaceutical excipients\nto enhance the aqueous solubility and alter the physicochemical properties of drugs that fall under\nclass II and IV categories according to the Biopharmaceutics Classification System (BPS). The\nindustrial significance of CDs became apparent during the 1970s as scientists started to discover\nmore of CD\u2019s potential in chemical modifications and the formation of inclusion complexes. CDs\ncan help in masking and prolonging the half-life of drugs used in cancer. Multiple optimization\ntechniques were discovered to prepare the derivatives of CDs and increase their complexation and\ndrug delivery efficiency. In recent years, due to the advancement of nanotechnology in pharmaceutical\nsectors, there has been growing interest in CDs. This review mainly focuses on the formulation\nof cyclodextrin conjugated nanocarriers using graphenes, carbon nanotubes, nanosponges, hydrogels,\ndendrimers, and polymers to achieve drug-release characteristics specific to cells. These\napproaches benefit the discovery of novel anti-cancer treatments, solubilization of new drug compounds,\nand cell specific drug delivery properties. Due to these unique properties of CDs, they are\nessential in achieving and enhancing tumor-specific cancer treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201818666211006103452","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T08:10:31Z","timestamp":1633680631000},"page":"266-300","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A New Approach for \u03b2-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1129-7084","authenticated-orcid":true,"given":"Palanirajan Vijayaraj","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, UCSI University, No. 1, Jalan Menara\nGading, Taman Connaught, Cheras, 56000 Kuala Lumpur, Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-0099","authenticated-orcid":true,"given":"Teng Meng","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, UCSI University, No. 1, Jalan Menara\nGading, Taman Connaught, Cheras, 56000 Kuala Lumpur, Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1162\/jiec.1999.3.2-3.192","volume":"3","author":"Ellis W.B.","year":"1999","unstructured":"Ellis W.B.; Books: Ullmann\u2019s encyclopedia of industrial chemistry. J Ind Ecol 1999,3(2-3),192-195","journal-title":"J Ind Ecol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/anie.198003441","volume":"19","author":"Saenger W.","year":"1980","unstructured":"Saenger W.; Cyclodextrin inclusion compounds in research and industry. Angew Chem Int Ed Engl 1980,19(5),344-362","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10847-006-9055-8","volume":"56","author":"Taira H.","year":"2006","unstructured":"Taira H.; Nagase H.; Endo T.; Ueda H.; Isolation, purification and characterization of large-ring cyclodextrins (CD 36\u223c&#x223C; CD 39). J Incl Phenom Macrocycl Chem 2006,56(1\u20132),23-28","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1021\/cr970022c","volume":"98","author":"Szejtli J.","year":"1998","unstructured":"Szejtli J.; Introduction and general overview of cyclodextrin chemistry. Chem Rev 1998,98(5),1743-1754","journal-title":"Chem Rev"},{"key":"ref=5","first-page":"8","author":"Das S.","year":"2017","unstructured":"Das S.; Roy D.;  Int J Curr Pharm Rev Res 2017,8","journal-title":"Int J Curr Pharm Rev Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.044","volume":"329","author":"Loftsson T.","year":"2007","unstructured":"Loftsson T.; Duch\u00eane D.; Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007,329(1-2),1-11","journal-title":"Int J Pharm"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"35764","DOI":"10.1038\/srep35764","volume":"6","author":"Saha S.","year":"2016","unstructured":"Saha S.; Roy A.; Roy K.; Roy M.N.; Study to explore the mechanism to form inclusion complexes of \u03b2-cyclodextrin with vitamin molecules. Sci Rep 2016,6,35764","journal-title":"Sci Rep"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ijpharm.2012.06.055","volume":"453","author":"Kurkov S.V.","year":"2013","unstructured":"Kurkov S.V.; Loftsson T.; Sergey V.K.; Thorsteinn L.; Cyclodextrins. Int J Pharm 2013,453(1),167-180","journal-title":"Int J Pharm"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1002\/jps.20992","volume":"96","author":"Loftsson T.","year":"2007","unstructured":"Loftsson T.; Vogensen S.B.; Brewster M.E.; Konr\u00e1dsd\u00f3ttir F.; Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci 2007,96(10),2532-2546","journal-title":"J Pharm Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3390\/molecules23051161","volume":"23","author":"Saokham P.","year":"2018","unstructured":"Saokham P.; Muankaew C.; Jansook P.; Loftsson T.; Solubility of cyclodextrins and drug\/cyclodextrin complexes. Molecules 2018,23(5),1161","journal-title":"Molecules"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nrd1576","volume":"3","author":"Davis M.E.","year":"2004","unstructured":"Davis M.E.; Brewster M.E.; Cyclodextrin-based pharmaceutics: Past, present and future. Nat Rev Drug Discov 2004,3(12),1023-1035","journal-title":"Nat Rev Drug Discov"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","volume":"59","author":"Brewster M.E.","year":"2007","unstructured":"Brewster M.E.; Loftsson T.; Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007,59(7),645-666","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","volume":"535","author":"Jansook P.","year":"2018","unstructured":"Jansook P.; Ogawa N.; Loftsson T.; Cyclodextrins: Structure, physicochemical properties and pharmaceutical applications. Int J Pharm 2018,535(1-2),272-284","journal-title":"Int J Pharm"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/acn3.306","volume":"3","author":"Davidson C.D.","year":"2016","unstructured":"Davidson C.D.; Fishman Y.I.; Pusk\u00e1s I.; Szem\u00e1n J.; Sohajda T.; McCauliff L.A.; Sikora J.; Storch J.; Vanier M.T.; Szente L.; Walkley S.U.; Dobrenis K.; Efficacy and ototoxicity of different cyclodextrins in Niemann-Pick C disease. Ann Clin Transl Neurol 2016,3(5),366-380","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11224-016-0884-9","volume":"28","author":"Szente L.","year":"2017","unstructured":"Szente L.; Fenyvesi \u00c9.; Cyclodextrin-Lipid complexes: Cavity size matters. Struct Chem 2017,28(2),479-492","journal-title":"Struct Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0021-9673(01)81457-6","volume":"452","author":"Armstrong D.W.","year":"1988","unstructured":"Armstrong D.W.; Faulkner J.R.; Han S.M.; Use of hydroxypropyl- and hydroxyethyl-derivatized \u03b2-cyclodextrins for the thin-layer chromatographic separation of enantiomers and diastereomers. J Chromatogr A 1988,452,323-330","journal-title":"J Chromatogr A"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1248\/cpb.47.1564","volume":"47","author":"Okada Y.","year":"1999","unstructured":"Okada Y.; Matsuda K.; Hara K.; Hamayasu K.; Hashimoto H.; Koizumi K.; Properties and the inclusion behavior of 6-O-&#x3B1;-D- galactosyl- and 6-O-&#x3B1;-D-mannosyl-cyclodextrins. Chem Pharm Bull (Tokyo) 1999,47(11),1564-1568","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1023\/A:1023067232328","volume":"44","author":"Tavornvipas S.","year":"2002","unstructured":"Tavornvipas S.; Arima H.; Hirayama F.; Uekama K.; Ishiguro T.; Oka M.; Hamayasu K.; Hashimoto H.; Some pharmaceutical properties of a new branched cyclodextrin, 6-O-&#x3B1;-(4-O-&#x3B1;-D-Glucuronyl)-D-Glucosyl\u03b2-Cyclodextrin. J Incl Phenom Macrocycl Chem 2002,44(1\u20134),391-394","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"ref=19","author":"Wimmer T.","year":"2000","unstructured":"Wimmer T.; Cyclodextrins. Ullmann\u2019s Encycl. Ind Chem 2000","journal-title":"Ind Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.drudis.2015.11.016","volume":"21","author":"Jambhekar S.S.","year":"2016","unstructured":"Jambhekar S.S.; Breen P.; Cyclodextrins in pharmaceutical formulations II: Solubilization, binding constant, and complexation efficiency. Drug Discov Today 2016,21(2),363-368","journal-title":"Drug Discov Today"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ddr.21452","volume":"79","author":"Jacob S.","year":"2018","unstructured":"Jacob S.; Nair A.B.; Cyclodextrin complexes: Perspective from drug delivery and formulation. Drug Dev Res 2018,79(5),201-217","journal-title":"Drug Dev Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.1081\/E-ESCS3-120012646","author":"Aicart E.","year":"2015","unstructured":"Aicart E.; Junquera E.;  Encyclopedia of surface and colloid science 2015,5566-5581","journal-title":"Encyclopedia of surface and colloid science"},{"key":"ref=23","volume":"4","author":"Connors K. A.","year":"1965","unstructured":"Connors K. A.; Higuchi T.; Phase solubility techniques. Adv Anal Chem Instrum 1965,4(2)","journal-title":"Adv Anal Chem Instrum"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijpharm.2005.05.042","volume":"302","author":"Loftsson T.","year":"2005","unstructured":"Loftsson T.; Hreinsd\u00f3ttir D.; M\u00e1sson M.; Evaluation of cyclodextrin solubilization of drugs. Int J Pharm 2005,302(1-2),18-28","journal-title":"Int J Pharm"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/03639049609069348","volume":"22","author":"Loftsson T.","year":"1996","unstructured":"Loftsson T.; Guo\u00af mundsd\u00f3ttir T. K.; Frio\u00af riksd\u00f3ttir h.; The influence of water-soluble polymers and ph on hydroxypropyl-&#x3B2;-Cyclodextrin complexation of drugs. Drug Dev Ind Pharm 1996,22(5),401-405","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1002\/jps.23077","volume":"101","author":"Loftsson T.","year":"2012","unstructured":"Loftsson T.; Brewster M.E.; Cyclodextrins as functional excipients: Methods to enhance complexation efficiency. J Pharm Sci 2012,101(9),3019-3032","journal-title":"J Pharm Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1081\/PDT-100100548","volume":"5","author":"Blanchard J.","year":"2000","unstructured":"Blanchard J.; Ugwu S.O.; Bhardwaj R.; Dorr R.T.; Development and testing of an improved parenteral formulation of phenytoin using 2-hydroxypropyl-&#x3B2;-cyclodextrin. Pharm Dev Technol 2000,5(3),333-338","journal-title":"Pharm Dev Technol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1208\/s12249-008-9055-7","volume":"9","author":"Loftsson T.","year":"2008","unstructured":"Loftsson T.; Vogensen S.B.; Desbos C.; Jansook P.; Carvedilol: Solubilization and cyclodextrin complexation: A technical note. AAPS PharmSciTech 2008,9(2),425-430","journal-title":"AAPS PharmSciTech"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"E184","DOI":"10.1208\/pt070379","volume":"7","author":"Chowdary K.P.R.","year":"2006","unstructured":"Chowdary K.P.R.; Srinivas S.V.; Influence of hydrophilic polymers on celecoxib complexation with hydroxypropyl \u03b2-cyclodextrin. AAPS PharmSciTech 2006,7(3),E184-E189","journal-title":"AAPS PharmSciTech"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0378-5173(03)00389-2","volume":"264","author":"He Y.","year":"2003","unstructured":"He Y.; Li P.; Yalkowsky S.H.; Solubilization of fluasterone in cosolvent\/cyclodextrin combinations. Int J Pharm 2003,264(1-2),25-34","journal-title":"Int J Pharm"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1023\/A:1008094702632","volume":"33","author":"Fenyvesi E.","year":"1999","unstructured":"Fenyvesi E.; Vikmon M.; Szeman J.; Redenti E.; Delcanale M.; Ventura P.; Szejtli J.; Interaction of hydroxy acids with \u03b2-cyclodextrin. J Incl Phenom Macrocycl Chem 1999,33(3),339-344","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ijpharm.2009.11.035","volume":"387","author":"Messner M.","year":"2010","unstructured":"Messner M.; Kurkov S.V.; Jansook P.; Loftsson T.; Self-assembled cyclodextrin aggregates and nanoparticles. Int J Pharm 2010,387(1-2),199-208","journal-title":"Int J Pharm"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ijpharm.2011.02.008","volume":"408","author":"Messner M.","year":"2011","unstructured":"Messner M.; Kurkov S.V.; Flavi\u00e0-Piera R.; Brewster M.E.; Loftsson T.; Self-assembly of cyclodextrins: The effect of the guest molecule. Int J Pharm 2011,408(1-2),235-247","journal-title":"Int J Pharm"},{"key":"ref=34","first-page":"536","volume":"11","author":"Loh G.O.K.","year":"2016","unstructured":"Loh G.O.K.; Tan Y.T.F.; Peh K-K.; Enhancement of norfloxacin solubilityvia inclusion complexation with \u03b2-cyclodextrin and its derivative hydroxypropyl-&#x3B2;-cyclodextrin. asian. J Pharm Sci 2016,11(4),536-546","journal-title":"J Pharm Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0378-5173(92)90244-V","volume":"87","author":"Ross D.L.","year":"1992","unstructured":"Ross D.L.; Riley C.M.; Physicochemical properties of the fluoroquinolone antimicrobials. III. complexation of lomefloxacin with various metal ions and the effect of metal ion complexation on aqueous solubility. Int J Pharm 1992,87(1\u20133),203-213","journal-title":"Int J Pharm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1023\/A:1016047215907","volume":"13","author":"Okimoto K.","year":"1996","unstructured":"Okimoto K.; Rajewski R.A.; Uekama K.; Jona J.A.; Stella V.J.; The interaction of charged and uncharged drugs with neutral (HP-&#x3B2;-CD) and anionically charged (SBE7-&#x3B2;-CD) \u03b2-cyclodextrins. Pharm Res 1996,13(2),256-264","journal-title":"Pharm Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1021\/js980109t","volume":"87","author":"Kim Y.","year":"1998","unstructured":"Kim Y.; Oksanen D.A.; Massefski W.; Blake J.F.; Duffy E.M.; Chrunyk B.; Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether. J Pharm Sci 1998,87(12),1560-1567","journal-title":"J Pharm Sci"},{"key":"ref=38","volume":"12","author":"Budhwar V.","year":"2018","unstructured":"Budhwar V.; Cyclodextrin complexes: an approach to improve the physicochemical properties of drugs and applications of cyclodextrin complexes. Asian J. Pharm.\n Asian J Pharm 2018,12(02)","journal-title":"Asian J Pharm"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jddst.2016.04.006","volume":"35","author":"Pereva S.","year":"2016","unstructured":"Pereva S.; Sarafska T.; Bogdanova S.; Spassov T.; Efficiency of \u201cCyclodextrin-Ibuprofen\u201d inclusion complex formation. J Drug Deliv Sci Technol 2016,35,34-39","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.lwt.2014.05.037","volume":"59","author":"Tao F.","year":"2014","unstructured":"Tao F.; Hill L.E.; Peng Y.; Gomes C.L.; Synthesis and characterization of \u03b2-cyclodextrin inclusion complexes of thymol and thyme oil for antimicrobial delivery applications. Lebensm Wiss Technol 2014,59(1),247-255","journal-title":"Lebensm Wiss Technol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.lwt.2015.12.017","volume":"68","author":"&#xDC;nl\u00fcsayin M.","year":"2016","unstructured":"&#xDC;nl\u00fcsayin M.; H\u0103d\u0103rug\u0103 N.G.; Rusu G.; Gruia A.T.; P\u0103unescu V.; H\u0103d\u0103rug\u0103 D.I.; Nano-encapsulation competitiveness of omega-3 fatty acids and correlations of thermal analysis and karl fischer water titration for european anchovy (Engraulis Encrasicolus L.) oil\/&#x3B2;-cyclodextrin complexes. Lebensm Wiss Technol 2016,68,135-144","journal-title":"Lebensm Wiss Technol"},{"key":"ref=42","author":"Hirayama F.","year":"1990","unstructured":"Hirayama F.; Uekama K.;  Methods of investigating and preparing inclusion compounds 1990","journal-title":"Methods of investigating and preparing inclusion compounds"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.3109\/03639049009058543","volume":"16","author":"Duch\u011bne D.","year":"1990","unstructured":"Duch\u011bne D.; Wouessidjewe D.; Pharmaceutical uses of cyclodextrins and derivatives. Drug Dev Ind Pharm 1990,16(17),2487-2499","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jpba.2016.07.024","volume":"129","author":"Mennini N.","year":"2016","unstructured":"Mennini N.; Maestrelli F.; Cirri M.; Mura P.; Analysis of physicochemical properties of ternary systems of oxaprozin with randomly methylated-&#xDF;-cyclodextrin and l-arginine aimed to improve the drug solubility. J Pharm Biomed Anal 2016,129,350-358","journal-title":"J Pharm Biomed Anal"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.enzmictec.2016.10.007","volume":"96","author":"Cao H.","year":"2017","unstructured":"Cao H.; Jiang Y.; Zhang H.; Nie K.; Lei M.; Deng L.; Wang F.; Tan T.; Enhancement of methanol resistance of Yarrowia lipolytica lipase 2 using \u03b2-cyclodextrin as an additive: Insights from experiments and molecular dynamics simulation. Enzyme Microb Technol 2017,96,157-162","journal-title":"Enzyme Microb Technol"},{"key":"ref=46","first-page":"1063","volume":"50","author":"Bratu I.","year":"2005","unstructured":"Bratu I.; Hernanz A.; Gavira J.M.; Bora G.H.; FT-IR Spectroscopy of inclusion complexes of beta-cyclodextrin with fenbufen and ibuprofen. Rom J Phys 2005,50(9\/10),1063","journal-title":"Rom J Phys"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.foodchem.2016.11.003","volume":"221","author":"Shrestha M.","year":"2017","unstructured":"Shrestha M.; Ho T.M.; Bhandari B.R.; Encapsulation of tea tree oil by amorphous beta-cyclodextrin powder. Food Chem 2017,221,1474-1483","journal-title":"Food Chem"},{"key":"ref=48","author":"Serafini M.R.","year":"2001","unstructured":"Serafini M.R.; Menezes P.P.; Costa L.P.; Lima C.M.; Quintans L.J.; Cardoso J.C.; Matos J.R.; Soares-Sobrinho J.L.; Grangeiro S.; Nunes P.S.; Interaction of p-cymene with \u03b2-cyclodextrin. J Therm Anal Calorim 2001","journal-title":"J Therm Anal Calorim"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1023\/A:1023022008337","volume":"44","author":"Junco S.","year":"2002","unstructured":"Junco S.; Casimiro T.; Ribeiro N.; Da Ponte M.N.; Marques H.C.; A Comparative study of naproxen\u2013beta cyclodextrin complexes prepared by conventional methods and using supercritical carbon dioxide. J Incl Phenom Macrocycl Chem 2002,44(1\u20134),117-121","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.carbpol.2016.07.013","volume":"152","author":"Aiassa V.","year":"2016","unstructured":"Aiassa V.; Zoppi A.; Becerra M.C.; Albesa I.; Longhi M.R.; Enhanced inhibition of bacterial biofilm formation and reduced leukocyte toxicity by chloramphenicol:&#x3B2;-cyclodextrin:N-acetylcysteine complex. Carbohydr Polym 2016,152,672-678","journal-title":"Carbohydr Polym"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0032-9592(03)00258-9","volume":"39","author":"Del Valle E.M.M.","year":"2004","unstructured":"Del Valle E.M.M.; Cyclodextrins and their uses: A review. Process Biochem 2004,39(9),1033-1046","journal-title":"Process Biochem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.carbpol.2013.05.084","volume":"98","author":"Miletic T.","year":"2013","unstructured":"Miletic T.; Kyriakos K.; Graovac A.; Ibric S.; Spray-dried voriconazole-cyclodextrin complexes: Solubility, dissolution rate and chemical stability. Carbohydr Polym 2013,98(1),122-131","journal-title":"Carbohydr Polym"},{"key":"ref=53","first-page":"1","volume":"2","author":"Cheirsilp B.","year":"2016","unstructured":"Cheirsilp B.; Rakmai J.; Inclusion complex formation of cyclodextrin with its guest and their applications. Biol Eng Med 2016,2(1),1-6","journal-title":"Biol Eng Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ejps.2016.09.032","volume":"96","author":"Thiry J.","year":"2017","unstructured":"Thiry J.; Krier F.; Ratwatte S.; Thomassin J-M.; Jerome C.; Evrard B.; Hot-melt extrusion as a continuous manufacturing process to form ternary cyclodextrin inclusion complexes. Eur J Pharm Sci 2017,96,590-597","journal-title":"Eur J Pharm Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"Lipinski C.A.","year":"2001","unstructured":"Lipinski C.A.; Lombardo F.; Dominy B.W.; Feeney P.J.; Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001,46(1-3),3-26","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=56","first-page":"17","volume":"1","author":"Lipinski C.A.","year":"2001","unstructured":"Lipinski C.A.; Avoiding investment in doomed drugs. Curr Drug Discov 2001,1,17-19","journal-title":"Curr Drug Discov"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2125.1988.tb03318.x","volume":"25","author":"Prentis R.A.","year":"1988","unstructured":"Prentis R.A.; Lis Y.; Walker S.R.; Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 1988,25(3),387-396","journal-title":"Br J Clin Pharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/978-3-319-15814-3_17","author":"Vromans H.","year":"2015","unstructured":"Vromans H.; Pauletti G.;  Practical Pharmaceutics 2015,347-356","journal-title":"Practical Pharmaceutics"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"10940","DOI":"10.1021\/cr500081p","volume":"114","author":"Crini G.","year":"2014","unstructured":"Crini G.; Review: A history of cyclodextrins. Chem Rev 2014,114(21),10940-10975","journal-title":"Chem Rev"},{"key":"ref=60","first-page":"117","volume":"4","author":"Higuchi T.","year":"1965","unstructured":"Higuchi T.; A phase solubility technique. Adv Anal Chem Instrum 1965,4,117-211","journal-title":"Adv Anal Chem Instrum"},{"key":"ref=61","first-page":"363","volume":"67","author":"Loftsson T.","year":"2012","unstructured":"Loftsson T.; Drug permeation through biomembranes: Cyclodextrins and the unstirred water layer. Pharmazie 2012,67(5),363-370","journal-title":"Pharmazie"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/jphp.12427","volume":"68","author":"Loftsson T.","year":"2016","unstructured":"Loftsson T.; Moya-Ortega M.D.; Alvarez-Lorenzo C.; Concheiro A.; Pharmacokinetics of cyclodextrins and drugs after oral and parenteral administration of drug\/cyclodextrin complexes. J Pharm Pharmacol 2016,68(5),544-555","journal-title":"J Pharm Pharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/jps.24331","volume":"104","author":"Leong N.J.","year":"2015","unstructured":"Leong N.J.; Prankerd R.J.; Shackleford D.M.; Mcintosh M.P.; The effect of intravenous sulfobutylether7 -&#x3B2;-cyclodextrin on the pharmacokinetics of a series of adamantane-containing compounds. J Pharm Sci 2015,104(4),1492-1498","journal-title":"J Pharm Sci"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1586\/17512433.2.1.37","volume":"2","author":"Naguib M.","year":"2009","unstructured":"Naguib M.; Brull S.J.; Sugammadex: A novel selective relaxant binding agent. Expert Rev Clin Pharmacol 2009,2(1),37-53","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=65","first-page":"231","volume":"43","author":"Brewster M.E.","year":"1989","unstructured":"Brewster M.E.; Simpkins J.W.; Hora M.S.; Stern W.C.; Bodor N.; The potential use of cyclodextrins in parenteral formulations. J Parenter Sci Technol 1989,43(5),231-240","journal-title":"J Parenter Sci Technol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/j.2042-7158.2010.01030.x","volume":"62","author":"Loftsson T.","year":"2010","unstructured":"Loftsson T.; Brewster M.E.; Pharmaceutical applications of cyclodextrins: Basic science and product development. J Pharm Pharmacol 2010,62(11),1607-1621","journal-title":"J Pharm Pharmacol"},{"key":"ref=67","unstructured":"Avaiable from: xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/itraconazole#section=Canonical-SMILES(accessed Dec 19, 2020)"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1034\/j.1600-0420.2002.800205.x","volume":"80","author":"Loftsson T.","year":"2002","unstructured":"Loftsson T.; Stef\u00e1nsson E.; Cyclodextrins in eye drop formulations: Enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand 2002,80(2),144-150","journal-title":"Acta Ophthalmol Scand"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ejmech.2005.11.002","volume":"41","author":"Ventura C.A.","year":"2006","unstructured":"Ventura C.A.; Giannone I.; Musumeci T.; Pignatello R.; Ragni L.; Landolfi C.; Milanese C.; Paolino D.; Puglisi G.; Physico- chemical characterization of disoxaril-dimethyl-&#x3B2;-cyclodextrin inclusion complex and in vitro permeation studies. Eur J Med Chem 2006,41(2),233-240","journal-title":"Eur J Med Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1248\/bpb1978.5.741","volume":"5","author":"Irie T.","year":"1982","unstructured":"Irie T.; Otagiri M.; Sunada M.; Uekama K.; Ohtani Y.; Yamada Y.; Sugiyama Y.; Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro. J Pharmacobiodyn 1982,5(9),741-744","journal-title":"J Pharmacobiodyn"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1021\/js9602453","volume":"86","author":"Fauvelle F.","year":"1997","unstructured":"Fauvelle F.; Debouzy J.C.; Crouzy S.; G\u00f6schl M.; Chapron Y.; Mechanism of \u03b1-cyclodextrin-induced hemolysis. 1. The two-step extraction of phosphatidylinositol from the membrane. J Pharm Sci 1997,86(8),935-943","journal-title":"J Pharm Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1351\/pac200476101825","volume":"76","author":"Szejtli J.","year":"2004","unstructured":"Szejtli J.; Past, present and futute of cyclodextrin research. Pure Appl Chem 2004,76(10),1825-1845","journal-title":"Pure Appl Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.bbrc.2004.05.145","volume":"320","author":"Gniadecki R.","year":"2004","unstructured":"Gniadecki R.; Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun 2004,320(1),165-169","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijpharm.2013.04.071","volume":"452","author":"Onodera R.","year":"2013","unstructured":"Onodera R.; Motoyama K.; Okamatsu A.; Higashi T.; Kariya R.; Okada S.; Arima H.; Involvement of cholesterol depletion from lipid rafts in apoptosis induced by methyl-&#x3B2;-cyclodextrin. Int J Pharm 2013,452(1-2),116-123","journal-title":"Int J Pharm"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ejps.2009.07.010","volume":"38","author":"Motoyama K.","year":"2009","unstructured":"Motoyama K.; Kameyama K.; Onodera R.; Araki N.; Hirayama F.; Uekama K.; Arima H.; Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-&#x3B2;-cyclodextrin, not 2,6-di-O-methyl-&#x3B1;-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells. Eur J Pharm Sci 2009,38(3),249-261","journal-title":"Eur J Pharm Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/bjc.1998.648","volume":"78","author":"Grosse P.Y.","year":"1998","unstructured":"Grosse P.Y.; Bressolle F.; Pinguet F.; Antiproliferative effect of methyl-&#x3B2;-cyclodextrin in vitro and in human tumour xenografted athymic nude mice. Br J Cancer 1998,78(9),1165-1169","journal-title":"Br J Cancer"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10847-010-9843-z","volume":"70","author":"Onodera R.","year":"2011","unstructured":"Onodera R.; Motoyama K.; Arima H.; Design and Evaluation of Folate-Appended Methyl-&#x3B2;-Cyclodextrin as a New Antitumor Agent. J Incl Phenom Macrocycl Chem 2011,70(3\u20134),321-326","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/srep01104","volume":"3","author":"Onodera R.","year":"2013","unstructured":"Onodera R.; Motoyama K.; Okamatsu A.; Higashi T.; Arima H.; Potential use of folate-appended methyl-&#x3B2;-cyclodextrin as an anticancer agent. Sci Rep 2013,3,1104","journal-title":"Sci Rep"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"e0141946","DOI":"10.1371\/journal.pone.0141946","volume":"10","author":"Yokoo M.","year":"2015","unstructured":"Yokoo M.; Kubota Y.; Motoyama K.; Higashi T.; Taniyoshi M.; Tokumaru H.; Nishiyama R.; Tabe Y.; Mochinaga S.; Sato A.; Sueoka-Aragane N.; Sueoka E.; Arima H.; Irie T.; Kimura S.; 2-hydroxypropyl-&#x3B2;-cyclodextrin acts as a novel anticancer agent. PLoS One 2015,10(11),e0141946","journal-title":"PLoS One"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-94-015-8277-3_3","author":"Fr\u00f6mming K-H.","year":"1994","unstructured":"Fr\u00f6mming K-H.; Szejtli J.;  Cyclodextrins in Pharmacy 1994,33-44","journal-title":"Cyclodextrins in Pharmacy"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1155\/2015\/198268","author":"Gidwani B.","year":"2015","unstructured":"Gidwani B.; Vyas A.; A comprehensive review on cyclodextrin-based carriers for delivery of chemotherapeutic cytotoxic anticancer drugs. In Cyclodextrins in Pharmacy; Springer 2015,33-44","journal-title":"In Cyclodextrins in Pharmacy; Springer"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"101448","DOI":"10.1016\/j.jddst.2019.101448","volume":"55","author":"Shahiwala A.","year":"2020","unstructured":"Shahiwala A.; Cyclodextrin conjugates for colon drug delivery. J Drug Deliv Sci Technol 2020,55,101448","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.bmc.2019.02.042","volume":"27","author":"Popio\u0142ek I.","year":"2019","unstructured":"Popio\u0142ek I.; Nizio\u0142ek A.; Kami\u0144ski K.; Kwolek U.; Nowakowska M.; Szczubia\u0142ka K.; Cellular delivery and enhanced anticancer activity of berberine complexed with a cationic derivative of \u03b3-cyclodextrin. Bioorg Med Chem 2019,27(7),1414-1420","journal-title":"Bioorg Med Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"115011","DOI":"10.1016\/j.carbpol.2019.115011","volume":"222","author":"Kim C.","year":"2019","unstructured":"Kim C.; Jeong D.; Kim S.; Kim Y.; Jung S.; Cyclodextrin functionalized agarose gel with low gelling temperature for controlled drug delivery systems. Carbohydr Polym 2019,222,115011","journal-title":"Carbohydr Polym"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jconrel.2017.11.042","volume":"270","author":"Gazzano E.","year":"2018","unstructured":"Gazzano E.; Rolando B.; Chegaev K.; Salaroglio I.C.; Kopecka J.; Pedrini I.; Saponara S.; Sorge M.; Buondonno I.; Stella B.; Marengo A.; Valoti M.; Brancaccio M.; Fruttero R.; Gasco A.; Arpicco S.; Riganti C.; Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. J Control Release 2018,270,37-52","journal-title":"J Control Release"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.carbpol.2019.04.024","volume":"216","author":"Yan C.","year":"2019","unstructured":"Yan C.; Liang N.; Li Q.; Yan P.; Sun S.; Biotin and arginine modified hydroxypropyl-&#x3B2;-cyclodextrin nanoparticles as novel drug delivery systems for paclitaxel. Carbohydr Polym 2019,216,129-139","journal-title":"Carbohydr Polym"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejpb.2010.12.022","volume":"78","author":"Sal\u00fastio P.J.","year":"2011","unstructured":"Sal\u00fastio P.J.; Cabral-Marques H.M.; Costa P.C.; Pinto J.F.; Comparison of ibuprofen release from minitablets and capsules containing ibuprofen: \u03b2-cyclodextrin complex. Eur J Pharm Biopharm 2011,78(1),58-66","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/tpj.2010.55","volume":"11","author":"Bonelli P.","year":"2011","unstructured":"Bonelli P.; Tuccillo F.M.; Calemma R.; Pezzetti F.; Borrelli A.; Martinelli R.; De Rosa A.; Esposito D.; Palaia R.; Castello G.; Changes in the gene expression profile of gastric cancer cells in response to ibuprofen: A gene pathway analysis. Pharmacogenomics J 2011,11(6),412-428","journal-title":"Pharmacogenomics J"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1039\/C7TB02551C","volume":"6","author":"Praphakar R.A.","year":"2018","unstructured":"Praphakar R.A.; Jeyaraj M.; Mehnath S.; Higuchi A.; Ponnamma D.; Sadasivuni K.K.; Rajan M.; A pH-sensitive guar gum- grafted-lysine-&#x3B2;-cyclodextrin drug carrier for the controlled release of 5-flourouracil into cancer cells. J Mater Chem B Mater Biol Med 2018,6(10),1519-1530","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/1061186X.2017.1339194","volume":"26","author":"Erdo\u011far N.","year":"2018","unstructured":"Erdo\u011far N.; Esenda\u011fl\u0131 G.; Nielsen T.T.; Esenda\u011fl\u0131-Y\u0131lmaz G.; Y\u00f6yen-Ermi\u015f D.; Erdo\u011fdu B.; Sargon M.F.; Ero\u011flu H.; Bilensoy E.; Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer. J Drug Target 2018,26(1),66-74","journal-title":"J Drug Target"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10847-017-0757-x","volume":"89","author":"Elamin K.M.","year":"2017","unstructured":"Elamin K.M.; Yamashita Y.; Motoyama K.; Higashi T.; Arima H.; Involvement of mitophagy-mediated cell death in colon cancer cells by folate-appended methyl-&#x3B2;-cyclodextrin. J Incl Phenom Macrocycl Chem 2017,89(3\u20134),333-342","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/1539445X.2019.1624265","volume":"17","author":"Fan W.","year":"2019","unstructured":"Fan W.; Xu Y.; Li Z.; Li Q.; Folic acid-modified \u03b2-cyclodextrin nanoparticles as drug delivery to load dox for liver cancer therapeutics. Soft Mater 2019,17(4),437-447","journal-title":"Soft Mater"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11051-017-4054-9","volume":"19","author":"Hsu Y-H.","year":"2017","unstructured":"Hsu Y-H.; Hsieh H-L.; Viswanathan G.; Voon S.H.; Kue C.S.; Saw W.S.; Yeong C.H.; Azlan C.A.; Imae T.; Kiew L.V.; Multifunctional carbon-coated magnetic sensing graphene oxide-cyclodextrin nanohybrid for potential cancer theranosis. J Nanopart Res 2017,19(11),359","journal-title":"J Nanopart Res"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.msec.2015.12.098","volume":"61","author":"Tan J.","year":"2016","unstructured":"Tan J.; Meng N.; Fan Y.; Su Y.; Zhang M.; Xiao Y.; Zhou N.; Hydroxypropyl-&#x3B2;-cyclodextrin-graphene oxide conjugates: Carriers for anti-cancer drugs. Mater Sci Eng C 2016,61,681-687","journal-title":"Mater Sci Eng C"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1016\/j.biomaterials.2014.01.040","volume":"35","author":"Liu T.","year":"2014","unstructured":"Liu T.; Xue W.; Ke B.; Xie M-Q.; Ma D.; Star-shaped cyclodextrin-poly(l-lysine) derivative co-delivering docetaxel and MMP-9 siRNA plasmid in cancer therapy. Biomaterials 2014,35(12),3865-3872","journal-title":"Biomaterials"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.msec.2018.04.020","volume":"89","author":"Siriviriyanun A.","year":"2018","unstructured":"Siriviriyanun A.; Tsai Y-J.; Voon S.H.; Kiew S.F.; Imae T.; Kiew L.V.; Looi C.Y.; Wong W.F.; Lee H.B.; Chung L.Y.; Cyclodextrin- and dendrimer-conjugated graphene oxide as a nanocarrier for the delivery of selected chemotherapeutic and photosensitizing agents. Mater Sci Eng C 2018,89,307-315","journal-title":"Mater Sci Eng C"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"36628","DOI":"10.1021\/acsami.8b08243","volume":"10","author":"Lee S.Y.","year":"2018","unstructured":"Lee S.Y.; Ko S-H.; Shim J-S.; Kim D-D.; Cho H-J.; Tumor targeting and lipid rafts disrupting hyaluronic acid-cyclodextrin-based nanoassembled structure for cancer therapy. ACS Appl Mater Interfaces 2018,10(43),36628-36640","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.msec.2019.01.068","volume":"98","author":"Reis C.A.","year":"2019","unstructured":"Reis C.A.; Rodrigues C.F.; Moreira A.F.; Jacinto T.A.; Ferreira P.; Correia I.J.; Development of gold-core silica shell nanospheres coated with poly-2-ethyl-oxazoline and \u03b2-cyclodextrin aimed for cancer therapy. Mater Sci Eng C 2019,98,960-968","journal-title":"Mater Sci Eng C"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.xphs.2018.03.021","volume":"107","author":"Shelley H.","year":"2018","unstructured":"Shelley H.; Babu R.J.; Role of cyclodextrins in nanoparticle-based drug delivery systems. J Pharm Sci 2018,107(7),1741-1753","journal-title":"J Pharm Sci"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2217\/nnm.14.41","volume":"9","author":"Lakkakula J.R.","year":"2014","unstructured":"Lakkakula J.R.; Ma\u00e7edo Krause R.W.; A vision for cyclodextrin nanoparticles in drug delivery systems and pharmaceutical applications. Nanomedicine (Lond) 2014,9(6),877-894","journal-title":"Nanomedicine (Lond)"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2174\/1381612822666160125114900","volume":"22","author":"Loureiro A.","year":"2016","unstructured":"Loureiro A.; Azoia N.G.; Gomes A.C.; Cavaco-Paulo A.; Albumin-based nanodevices as drug carriers. Curr Pharm Des 2016,22(10),1371-1390","journal-title":"Curr Pharm Des"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"6975","DOI":"10.1039\/D0TB00575D","volume":"8","author":"Nishida K.","year":"2020","unstructured":"Nishida K.; Tamura A.; Kang T.W.; Masuda H.; Yui N.; An antibody-supermolecule conjugate for tumor-specific targeting of tumoricidal methylated \u03b2-cyclodextrin-threaded polyrotaxanes. J Mater Chem B Mater Biol Med 2020,8(31),6975-6987","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"7886","DOI":"10.1021\/acs.inorgchem.9b00570","volume":"58","author":"Thiabaud G.","year":"2019","unstructured":"Thiabaud G.; Harden-Bull L.; Ghang Y-J.; Sen S.; Chi X.; Bachman J.L.; Lynch V.M.; Siddik Z.H.; Sessler J.L.; Platinum(IV)-ferrocene conjugates and their cyclodextrin host-guest complexes. Inorg Chem 2019,58(12),7886-7894","journal-title":"Inorg Chem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/ejic.201301282","volume":"2014","author":"Banfi\u0107 J.","year":"2014","unstructured":"Banfi\u0107 J.; Legin A.A.; Jakupec M.A.; Galanski M.; Keppler B.K.; Platinum (IV) complexes featuring one or two axial ferrocene bearing ligands\u2013synthesis, characterization, and cytotoxicity. Eur J Inorg Chem 2014,2014(3),484-492","journal-title":"Eur J Inorg Chem"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"13793","DOI":"10.1021\/acsami.6b03474","volume":"8","author":"Jana B.","year":"2016","unstructured":"Jana B.; Mohapatra S.; Mondal P.; Barman S.; Pradhan K.; Saha A.; Ghosh S.; \u03b1-cyclodextrin interacts close to vinblastine site of tubulin and delivers curcumin preferentially to the tubulin surface of cancer cell. ACS Appl Mater Interfaces 2016,8(22),13793-13803","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s11095-012-0700-1","volume":"29","author":"Dandawate P.R.","year":"2012","unstructured":"Dandawate P.R.; Vyas A.; Ahmad A.; Banerjee S.; Deshpande J.; Swamy K.V.; Jamadar A.; Dumhe-Klaire A.C.; Padhye S.; Sarkar F.H.; Inclusion complex of novel curcumin analogue CDF and \u03b2-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. Pharm Res 2012,29(7),1775-1786","journal-title":"Pharm Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.bmcl.2015.12.060","volume":"26","author":"Ndong Ntoutoume G.M.A.","year":"2016","unstructured":"Ndong Ntoutoume G.M.A.; Granet R.; Mbakidi J.P.; Br\u00e9gier F.; L\u00e9ger D.Y.; Fidanzi-Dugas C.; Lequart V.; Joly N.; Liagre B.; Chaleix V.; Sol V.; Development of curcumin-cyclodextrin\/cellulose nanocrystals complexes: New anticancer drug delivery systems. Bioorg Med Chem Lett 2016,26(3),941-945","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3109\/10717544.2012.721143","volume":"19","author":"Rahman S.","year":"2012","unstructured":"Rahman S.; Cao S.; Steadman K.J.; Wei M.; Parekh H.S.; Native and \u03b2-cyclodextrin-enclosed curcumin: Entrapment within liposomes and their in vitro cytotoxicity in lung and colon cancer. Drug Deliv 2012,19(7),346-353","journal-title":"Drug Deliv"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.etap.2016.09.021","volume":"48","author":"Zhang L.","year":"2016","unstructured":"Zhang L.; Man S.; Qiu H.; Liu Z.; Zhang M.; Ma L.; Gao W.; Curcumin-cyclodextrin complexes enhanced the anti-cancer effects of curcumin. Environ Toxicol Pharmacol 2016,48,31-38","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/JPRI\/2018\/39890","volume":"21","author":"Patel H.","year":"2018","unstructured":"Patel H.; Trivedi M.; Maniar M.; Ren C.; Dave R.; Effect of \u03b2- cyclodextrin and hydroxypropyl \u03b2-cyclodextrin on aqueous stability, solubility and dissolution of novel anti-cancer drug rigosertib. J Pharm Res Int 2018,21(3),1-20","journal-title":"J Pharm Res Int"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bmcl.2019.03.003","volume":"29","author":"Granet R.","year":"2019","unstructured":"Granet R.; Faure R.; Ndong Ntoutoume G.M.A.; Mbakidi J.P.; Leger D.Y.; Liagre B.; Sol V.; Enhanced cytotoxicity of gold porphyrin complexes after inclusion in cyclodextrin scaffolds adsorbed on polyethyleneimine-coated gold nanoparticles. Bioorg Med Chem Lett 2019,29(9),1065-1068","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.carbpol.2016.04.062","volume":"148","author":"Lu S.","year":"2016","unstructured":"Lu S.; Wang A.; Ma Y.J.; Xuan H.Y.; Zhao B.; Li X.D.; Zhou J.H.; Zhou L.; Wei S.H.; Cyclodextrin type dependent host-guest interaction mode with phthalocyanine and their influence on photodynamic activity to cancer. Carbohydr Polym 2016,148,236-242","journal-title":"Carbohydr Polym"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/08982104.2019.1579838","volume":"30","author":"Shen Q.","year":"2020","unstructured":"Shen Q.; Shen Y.; Jin F.; Du Y.Z.; Ying X.Y.; Paclitaxel\/hydroxypropyl-&#x3B2;-cyclodextrin complex-loaded liposomes for overcoming multidrug resistance in cancer chemotherapy. J Liposome Res 2020,30(1),12-20","journal-title":"J Liposome Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10847-006-9259-y","volume":"57","author":"Bilensoy E.","year":"2007","unstructured":"Bilensoy E.; C\u0131rpanl\u0131 Y.; \u015een M.; Do\u011fan A.L.; \u00c7al\u0131&#x15F; S.; Thermosensitive Mucoadhesive Gel Formulation Loaded with 5-Fu: Cyclodextrin complex for hpv-induced cervical cancer. J Incl Phenom Macrocycl Chem 2007,57(1\u20134),363-370","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3109\/10837450.2014.979945","volume":"21","author":"Gidwani B.","year":"2016","unstructured":"Gidwani B.; Vyas A.; Formulation, characterization and evaluation of cyclodextrin-complexed bendamustine-encapsulated PLGA nanospheres for sustained delivery in cancer treatment. Pharm Dev Technol 2016,21(2),161-171","journal-title":"Pharm Dev Technol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ijbiomac.2018.10.181","volume":"122","author":"Vaidya B.","year":"2019","unstructured":"Vaidya B.; Parvathaneni V.; Kulkarni N.S.; Shukla S.K.; Damon J.K.; Sarode A.; Kanabar D.; Garcia J.V.; Mitragotri S.; Muth A.; Gupta V.; Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. Int J Biol Macromol 2019,122,338-347","journal-title":"Int J Biol Macromol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1166\/jbn.2009.1075","volume":"5","author":"Marslin G.","year":"2009","unstructured":"Marslin G.; Sheeba C.J.; Kalaichelvan V.K.; Manavalan R.; Reddy P.N.; Franklin G.; Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces Erlotinib-induced subacute toxicity in rat. J Biomed Nanotechnol 2009,5(5),464-471","journal-title":"J Biomed Nanotechnol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/jps.21946","volume":"99","author":"Gupta V.","year":"2010","unstructured":"Gupta V.; Rawat A.; Ahsan F.; Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension. J Pharm Sci 2010,99(4),1774-1789","journal-title":"J Pharm Sci"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jconrel.2018.09.025","volume":"290","author":"Guimaraes P.P.G.","year":"2018","unstructured":"Guimaraes P.P.G.; Tan M.; Tammela T.; Wu K.; Chung A.; Oberli M.; Wang K.; Spektor R.; Riley R.S.; Viana C.T.R.; Jacks T.; Langer R.; Mitchell M.J.; Potent in vivo lung cancer Wnt signaling inhibitionvia cyclodextrin-LGK974 inclusion complexes. J Control Release 2018,290,75-87","journal-title":"J Control Release"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.phymed.2018.11.012","volume":"57","author":"Hu S.C-S.","year":"2019","unstructured":"Hu S.C-S.; Lai Y-C.; Lin C-L.; Tzeng W-S.; Yen F-L.; Inclusion complex of saikosaponin-d with hydroxypropyl-&#x3B2;-cyclodextrin: Improved physicochemical properties and anti-skin cancer activity. Phytomedicine 2019,57,174-182","journal-title":"Phytomedicine"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jff.2017.12.023","volume":"41","author":"Catchpole O.","year":"2018","unstructured":"Catchpole O.; Mitchell K.; Bloor S.; Davis P.; Suddes A.; Anti- gastrointestinal cancer activity of cyclodextrin-encapsulated propolis. J Funct Foods 2018,41,1-8","journal-title":"J Funct Foods"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.fct.2019.01.003","volume":"125","author":"Trindade G.G.G.","year":"2019","unstructured":"Trindade G.G.G.; Thrivikraman G.; Menezes P.P.; Fran\u00e7a C.M.; Lima B.S.; Carvalho Y.M.B.G.; Souza E.P.B.S.S.; Duarte M.C.; Shanmugam S.; Quintans-J\u00fanior L.J.; Bezerra D.P.; Bertassoni L.E.; Ara\u00fajo A.A.S.; Carvacrol\/&#x3B2;-cyclodextrin inclusion complex inhibits cell proliferation and migration of prostate cancer cells. Food Chem Toxicol 2019,125,198-209","journal-title":"Food Chem Toxicol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s13204-018-0798-5","volume":"8","author":"Enoch I.V.M.V.","year":"2018","unstructured":"Enoch I.V.M.V.; Ramasamy S.; Mohiyuddin S.; Gopinath P.; Manoharan R.; Cyclodextrin\u2013PEG conjugate-wrapped magnetic ferrite nanoparticles for enhanced drug loading and release. Appl Nanosci 2018,8(3),273-284","journal-title":"Appl Nanosci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.carbpol.2019.02.075","volume":"213","author":"Gholibegloo E.","year":"2019","unstructured":"Gholibegloo E.; Mortezazadeh T.; Salehian F.; Ramazani A.; Amanlou M.; Khoobi M.; Improved curcumin loading, release, solubility and toxicity by tuning the molar ratio of cross-linker to \u03b2-cyclodextrin. Carbohydr Polym 2019,213,70-78","journal-title":"Carbohydr Polym"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1039\/c3cc40542g","volume":"49","author":"Liang W.","year":"2013","unstructured":"Liang W.; Yang C.; Zhou D.; Haneoka H.; Nishijima M.; Fukuhara G.; Mori T.; Castiglione F.; Mele A.; Caldera F.; Trotta F.; Inoue Y.; Phase-controlled supramolecular photochirogenesis in cyclodextrin nanosponges. Chem Commun (Camb) 2013,49(34),3510-3512","journal-title":"Chem Commun (Camb)"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.carbpol.2019.03.017","volume":"213","author":"Bai Y.","year":"2019","unstructured":"Bai Y.; Liu C.P.; Xie F.Y.; Ma R.; Zhuo L.H.; Li N.; Tian W.; Construction of \u03b2-cyclodextrin-based supramolecular hyperbranched polymers self-assemblies using AB-type macromonomer and their application in the drug delivery field. Carbohydr Polym 2019,213,411-418","journal-title":"Carbohydr Polym"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1021\/ma300693h","volume":"45","author":"Huan X.","year":"2012","unstructured":"Huan X.; Wang D.; Dong R.; Tu C.; Zhu B.; Yan D.; Zhu X.; Supramolecular ABC miktoarm star terpolymer based on host\u2013guest inclusion complexation. Macromolecules 2012,45(15),5941-5947","journal-title":"Macromolecules"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1002\/adfm.201203762","volume":"23","author":"Durmaz Y.Y.","year":"2013","unstructured":"Durmaz Y.Y.; Lin Y.; ElSayed M.E.H.; Development of Degradable, PH\u2010sensitive star vectors for enhancing the cytoplasmic delivery of nucleic acids. Adv Funct Mater 2013,23(31),3885-3895","journal-title":"Adv Funct Mater"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.colsurfb.2014.09.025","volume":"123","author":"Iannazzo D.","year":"2014","unstructured":"Iannazzo D.; Mazzaglia A.; Scala A.; Pistone A.; Galvagno S.; Lanza M.; Riccucci C.; Ingo G.M.; Colao I.; Sciortino M.T.; Valle F.; Piperno A.; Grassi G.; \u03b2-Cyclodextrin-grafted on multiwalled carbon nanotubes as versatile nanoplatform for entrapment of guanine-based drugs. Colloids Surf B Biointerfaces 2014,123,264-270","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.colsurfb.2019.05.011","volume":"180","author":"Liu H.","year":"2019","unstructured":"Liu H.; Chen J.; Li X.; Deng Z.; Gao P.; Li J.; Ren T.; Huang L.; Yang Y.; Zhong S.; Amphipathic \u03b2-cyclodextrin nanocarriers serve as intelligent delivery platform for anticancer drug. Colloids Surf B Biointerfaces 2019,180,429-440","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jcis.2019.04.096","volume":"551","author":"Xue Q.","year":"2019","unstructured":"Xue Q.; Ye C.; Zhang M.; Hu X.; Cai T.; Glutathione responsive cubic gel particles cyclodextrin metal-organic frameworks for intracellular drug delivery. J Colloid Interface Sci 2019,551,39-46","journal-title":"J Colloid Interface Sci"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1039\/C4TB01351D","volume":"3","author":"Gu W-X.","year":"2015","unstructured":"Gu W-X.; Zhu M.; Song N.; Du X.; Yang Y-W.; Gao H.; Reverse micelles based on biocompatible \u03b2-cyclodextrin conjugated polyethylene glycol block polylactide for protein delivery. J Mater Chem B Mater Biol Med 2015,3(2),316-322","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.carbpol.2018.03.097","volume":"193","author":"Bai S.","year":"2018","unstructured":"Bai S.; Hou M.; Shi X.; Chen J.; Ma X.; Gao Y-E.; Wang Y.; Xue P.; Kang Y.; Xu Z.; Reduction-active polymeric prodrug micelles based on \u03b1-cyclodextrin polyrotaxanes for triggered drug release and enhanced cancer therapy. Carbohydr Polym 2018,193,153-162","journal-title":"Carbohydr Polym"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/00914037.2018.1493686","volume":"68","author":"Cui X.","year":"2019","unstructured":"Cui X.; Wang N.; Wang H.; Li G.; Tao Q.; PH sensitive supramolecular vesicles from cyclodextrin graft copolymer and benzimidazole ended block copolymer as dual drug carriers. Int J Polym Mater Polym Biomater 2019,68(12),733-740","journal-title":"Int J Polym Mater Polym Biomater"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.2147\/IJN.S193170","volume":"14","author":"Yang T.","year":"2019","unstructured":"Yang T.; Du G.; Cui Y.; Yu R.; Hua C.; Tian W.; Zhang Y.; pH-sensitive doxorubicin-loaded polymeric nanocomplex based on \u03b2-cyclodextrin for liver cancer-targeted therapy. Int J Nanomedicine 2019,14,1997-2010","journal-title":"Int J Nanomedicine"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"23197","DOI":"10.1021\/acsami.5b07033","volume":"7","author":"Correia A.","year":"2015","unstructured":"Correia A.; Shahbazi M-A.; M\u00e4kil\u00e4 E.; Almeida S.; Salonen J.; Hirvonen J.; Santos H.A.; Cyclodextrin-modified porous silicon nanoparticles for efficient sustained drug delivery and proliferation inhibition of breast cancer cells. ACS Appl Mater Interfaces 2015,7(41),23197-23204","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"25633","DOI":"10.1039\/C6RA03839E","volume":"6","author":"Qiu J.","year":"2016","unstructured":"Qiu J.; Kong L.; Cao X.; Li A.; Tan H.; Shi X.; Dendrimer-entrapped gold nanoparticles modified with \u03b2-cyclodextrin for enhanced gene delivery applications. RSC Advances 2016,6(31),25633-25640","journal-title":"RSC Advances"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1021\/js960213f","volume":"86","author":"Irie T.","year":"1997","unstructured":"Irie T.; Uekama K.; Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997,86(2),147-162","journal-title":"J Pharm Sci"},{"key":"ref=139","year":"2014","unstructured":"Background Review for Cyclodextrins Used as Excipients 2014","journal-title":"Background Review for Cyclodextrins Used as Excipients"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/jn\/123.4.676","volume":"123","author":"Flouri\u00e9 B.","year":"1993","unstructured":"Flouri\u00e9 B.; Molis C.; Achour L.; Dupas H.; Hatat C.; Rambaud J.C.; Fate of \u03b2-cyclodextrin in the human intestine. J Nutr 1993,123(4),676-680","journal-title":"J Nutr"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jcph.1077","volume":"58","author":"Hoover R.K.","year":"2018","unstructured":"Hoover R.K.; Alcorn H.; Lawrence L.; Paulson S.K.; Quintas M.; Luke D.R.; Cammarata S.K.; Clinical pharmacokinetics of sulfobutylether-&#x3B2;-cyclodextrin in patients with varying degrees of renal impairment. J Clin Pharmacol 2018,58(6),814-822","journal-title":"J Clin Pharmacol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.fct.2005.03.007","volume":"43","author":"Gould S.","year":"2005","unstructured":"Gould S.; Scott R.C.; 2-Hydroxypropyl-&#x3B2;-cyclodextrin (HP-&#x3B2;-CD): A toxicology review. Food Chem Toxicol [sssss].2005,43(10),1451-1459","journal-title":"Food Chem Toxicol"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201818666211006103452","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/197030\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201818666211006103452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:49:21Z","timestamp":1671274161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/197030\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":142,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201818666211006103452","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}